HyperMed, Inc.

HyperMed, Inc. specializes in advanced medical hyperspectral imaging technology, focusing on surface tissue oximetry to improve clinical decision-making in healthcare. Founded in 1997 in Burlington, US, HyperMed Imaging, Inc. provides innovative imaging solutions for healthcare.

The company has undergone strategic pivots to enhance its product offerings and has raised USD 2. 00 mn in a Series B funding round in May 2015, backed by Biomark Capital and DSW Investments. CEO Mark Darty leads the company in its mission to deliver critical imaging solutions. HyperMed Imaging, Inc.

specializes in medical hyperspectral imaging technology, particularly in surface tissue oximetry. Its flagship products, OxyVu™-1 and HyperView™, assess critical biomarkers including oxyhemoglobin, deoxyhemoglobin, and oxygen saturation in superficial tissues, aiding clinicians in evaluating tissue health and local vascular systems, essential for managing ischemic conditions and non-healing wounds. These products are utilized primarily in hospitals, surgical centers, and clinics across North America and select international markets. HyperMed Imaging, Inc.

generates revenue primarily through direct sales of its advanced imaging systems, including its proprietary products HyperView™ and OxyVu™-1. Sales are conducted through contracts with healthcare facilities for imaging equipment and support services, alongside B2B partnerships that encompass training and maintenance. The financial agreements with clients ensure clarity on pricing plans and product costs. HyperMed Imaging plans to utilize the recent Series B financing of USD 2.

00 mn raised in May 2015 to support the development of new products aimed at enhancing their imaging technology. The company is also targeting expansion into additional markets, specifically aiming to penetrate European and Asian healthcare sectors by 2025. This growth strategy aligns with their commitment to innovate and improve clinician access to vital imaging insights.